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Background/Aims: The disease course and factors associ-
ated with poor prognosis in Korean patients with Crohn’s 
disease (CD) have not been fully determined. The aim of 
this study was to explore potential associations between 
the clinical characteristics and long-term outcomes of CD 
and perianal fistulas in a Korean population. Methods: The 
retrospective Crohn’s Disease Clinical Network and Cohort 
(CONNECT) study enrolled patients diagnosed with CD be-
tween July 1982 and December 2008 from 32 hospitals. 
Those followed for <12 months were excluded. Clinical 
outcomes were CD-related surgery and complications, in-
cluding nonperianal fistulas, strictures, and intra-abdominal 
abscesses. Results: The mean follow-up period was 8.77 
years (range, 1.0 to 25.8 years). A total of 1,193 CD patients 
were enrolled, of whom 465 (39.0%) experienced perianal 
fistulas. Perianal fistulizing CD was significantly associated 
with younger age, male gender, CD diagnosed at primary 
care clinics, and ileocolonic involvement. Both nonperianal 
fistulas (p=0.034) and intra-abdominal abscesses (p=0.020) 
were significantly more common in CD patients with perianal 
fistulas than in those without perianal fistulas. The rates of 
complicated strictures and CD-related surgery were similar 
between the groups. Independently associated factors of 
nonperianal fistulas were perianal fistulas (p=0.015), fe-
male gender (p=0.048), CD diagnosed at referral hospital 
(p=0.003), and upper gastrointestinal (UGI) involvement 
(p=0.001). Furthermore, perianal fistulas (p=0.048) and 
UGI involvement (p=0.012) were independently associated 
with the risk of intra-abdominal abscesses. Conclusions: 
Perianal fistulas predicted the development of nonperianal 
fistulas and intra-abdominal abscesses in Korean CD pa-
tients. Therefore, patients with perianal fistulizing CD should 
be carefully monitored for complicated fistulas or abscesses. 
(Gut Liver 2018;12:544-554)
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INTRODUCTION
Crohn’s disease (CD) is a chronic and relapsing inflammatory 
disorder characterized by transmural inflammation that oc-
curs in the gastrointestinal tract.1,2 It has been recognized as an 
immune-mediated disease that can results in impaired quality 
of life and serious complications including fibrotic strictures, 
intestinal fistulas, and intra-abdominal abscesses.3,4 Although 
the pathogenesis of CD remains unclear, accumulating evidence 
suggests that complex interactions between genetic and envi-
ronmental factors are closely related to the development and 
perpetuation of intestinal inflammation.5-7 
Recently, the incidence and prevalence of CD have been 
increasing in East Asia.1,8 This could be due to environmental 
changes such as Westernization of diet and lifestyle.9 However, 
the genetic susceptibilities and epidemiological characteristics 
of CD in East Asians are thought to differ from those in Cau-
 This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0) 
which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Gut and Liver, Vol. 12, No. 5, September 2018, pp. 544-554
Association of Perianal Fistulas with Clinical Features and Prognosis of 
Crohn’s Disease in Korea: Results from the CONNECT Study
Jaeyoung Chun1, Jong Pil Im1, Ji Won Kim2, Kook Lae Lee2, Chang Hwan Choi3, Hyunsoo Kim4, Jae Hee Cheon5, 
Byong Duk Ye6, Young-Ho Kim7, You Sun Kim8, Yoon Tae Jeen9, Dong Soo Han10, Won Ho Kim5, and Joo Sung Kim1
1Department of Internal Medicine and Liver Research Institute, Seoul National University College of Medicine, 2Department of Internal 
Medicine, Seoul Metropolitan Government-Seoul National University Boramae Medical Center, Seoul National University College of Medicine, 
3Department of Internal Medicine, Chung-Ang University College of Medicine, Seoul, 4Department of Internal Medicine, Chonnam National 
University Medical School, Gwangju, 5Department of Internal Medicine, Yonsei University College of Medicine, 6Department of Internal 
Medicine, University of Ulsan College of Medicine, 7Department of Internal Medicine, Sungkyunkwan University School of Medicine, 
8Department of Internal Medicine, Inje University College of Medicine, 9Department of Internal Medicine, Korea University College of Medicine, 
Seoul, and 10Department of Internal Medicine, Hanyang University College of Medicine, Guri, Korea
Correspondence to: Ji Won Kim
Department of Internal Medicine, Seoul Metropolitan Government-Seoul National University Boramae Medical Center, Seoul National University 
College of Medicine, 20 Boramae-ro 5-gil, Dongjak-gu, Seoul 07061, Korea 
Tel: +82-2-870-2221, Fax: +82-2-870-3863, E-mail: kjwjor@snu.ac.kr 
Received on March 27, 2018. Revised on June 13, 2018. Accepted on June 19, 2018. 
pISSN 1976-2283  eISSN 2005-1212  https://doi.org/10.5009/gnl18157
Jaeyoung Chun and Jong Pil Im contributed equally to this work as first authors.
 Chun J, et al: Perianal Fistulas in Crohn’s Disease  545
casians. For example, nucleotide-binding oligomerization do-
main protein 2/caspase recruitment domain protein 15 (NOD2/
CARD15) mutations, which are common genetic variants for 
susceptibility to CD in Caucasians,10,11 are reported to have no 
association with CD in Korean,12 Japanese,13 and Chinese popu-
lations.14 Furthermore, East Asian CD patients have ileocolonic 
involvement more often than Caucasians.15,16 Because of the dif-
ferences between East Asians and Caucasians in both genotypes 
and phenotypes of CD, it is important to define the specific 
clinical characteristics of Korean CD patients in order to select 
appropriate treatment strategies. However, the disease course 
and factors associated with poor prognosis for CD in Koreans 
have not been fully determined.
Perianal fistula is detected in up to 90% of CD patients with 
rectal involvement.17 Compared to Western countries, the preva-
lence of perianal complication is likely to be higher in East Asia, 
ranging from 30.3% to 58.8%.17 Perianal lesions present with 
a spectrum of clinical severity from asymptomatic to severe 
diseases requiring repeated surgical interventions with medi-
cal treatment including antibiotics and tumor necrosis factor 
(TNF)-α antagonists in patients with CD.18 In addition, perianal 
complications generally denote an aggressive and disabling 
phenotype of CD.19 However, the relationships between the 
presence of perianal fistula and the development of CD-related 
complications including nonperianal fistulas, strictures, or intra-
abdominal abscesses remain unclear, particularly in East Asians. 
Thus, the aim of this study was to assess the clinical character-
istics and long-term outcomes of CD in terms of potential asso-
ciations with perianal fistulas in a Korean population.
MATERIALS AND METHODS
1. Study population 
The Crohn’s Disease Clinical Network and Cohort (CONNECT) 
study included patients diagnosed with CD between July 1982 
and December 2008 from 32 hospitals in Korea.20-24 The aims 
of this retrospective multicenter cohort study were as follows: 
(1) to determine epidemiological and clinical characteristics by 
establishing a registered database of CD patients; (2) to establish 
a genetic research management system for CD patients; (3) to 
establish a network of patients and of doctors who specialize 
in the management of CD in the form of a private nonprofit 
organization; and (4) to develop Korean-specific diagnostic and 
therapeutic guidelines for CD.20 All subjects were diagnosed 
and treated by inflammatory bowel disease (IBD) specialists 
who were members of the Korean Association for the Study of 
Intestinal Diseases. CD was diagnosed on the basis of clinical, 
radiological, endoscopic, and pathological criteria.15,25 Patients 
who were diagnosed with indeterminate colitis, intestinal tu-
berculosis, or intestinal Behçet’s disease were excluded from 
this cohort. Patients with a follow-up period of <12 months or 
incomplete medical records were also excluded. This study was 
approved by the institutional review boards at the participating 
medical centers.
2. Study protocol 
The medical records of all subjects were reviewed at each par-
ticipating hospital until May 2014. We evaluated demographic 
data and clinical characteristics including age at diagnosis, 
gender, family history of IBD, hospital where patients were 
diagnosed with CD, exposure to antituberculosis medication, 
disease location, history of perianal fistulas, medical therapy for 
CD, and disease-related complications (i.e., nonperianal fistu-
las, strictures, and intra-abdominal abscess formation) during 
follow-up of the cohort. Age at diagnosis and disease location 
were classified according to the revised Montreal classification.26 
Briefly, age at diagnosis (A1, ≤16 years; A2, 17–40 years; and 
A3, >40 years) and location criteria (L1, small bowel; L2, colon; 
L3, small bowel and colon; and L4, upper gastrointestinal [UGI] 
tract) were noted. With respect to perianal fistulas, the diagnosis 
was based on physical examination and endoscopic and/or ra-
diological findings.27 The detection time of perianal fistulas was 
also collected. 
Clinical outcomes were CD-related surgery and complications 
including nonperianal fistulas, strictures, and intra-abdominal 
abscesses. Nonperianal fistulas (Montreal classification B3) were 
defined as the development of enteroenteric, enterovesical, or 
enterocutaneous fistulas.26,28 Strictures (Montreal classification 
B2) were defined as the occurrence of constant luminal narrow-
ing demonstrated by radiological, endoscopic, and/or pathologi-
cal findings.26,28 The detection of strictures required obstructive 
signs/symptoms or prestenotic dilatation. Intra-abdominal 
abscesses were defined as extraintestinal fluid collection located 
in the peritoneal cavity, abdominal wall, or subphrenic region.29 
Abscess formation located in the anal region was excluded. CD-
related surgery was defined as intestinal resection for medical 
refractoriness and/or complications of CD except perianal le-
sions. Time to the first occurrence of each outcome from diag-
nosis of CD was calculated in months. 
3. Statistical analysis 
Statistical analysis was performed with SPSS version 17.0 
(SPSS Inc., Chicago, IL, USA). Pearson chi-square test, Fisher 
exact test, and Student t-test were used, as appropriate, to 
calculate the statistical significance of the demographic and 
clinical variables, according to the presence and detection 
time of perianal fistulas. Rates of clinical outcomes including 
nonperianal fistulas, strictures, intra-abdominal abscesses and 
surgery were calculated with actuarial life tables. The Kaplan-
Meier method was used to estimate the cumulative probability 
of clinical outcomes. Log-rank test was performed to determine 
the significance of perianal fistulas with respect to difference for 
each clinical outcome. Multivariable analysis with Cox propor-
tional hazards models was performed to identify independent 
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associated factors for nonperianal fistulas and intra-abdominal 
abscesses. A p-value <0.05 was considered statistically signifi-
cant.
RESULTS
1. Baseline demographic and clinical characteristics 
We reviewed the medical records of 1,382 patients who were 
diagnosed with CD between July 1982 and December 2008 in 
this cohort. All subjects were ethnically Korean. We excluded 
189 of these patients (13.7%) due to a follow-up duration of 
<12 months (75 patients) or incomplete medical records (114 
patients). A total of 1,193 CD patients were finally enrolled in 
the study (Fig. 1). 
The study population comprised 840 men (70.4%). The mean 
age at diagnosis of CD was 26.9±11.9 years (range, 0 to 77 
years). The mean follow-up period was 8.77 years (range, 1.0 
to 25.8 years). At the discretion of the physicians, 280 patients 
(23.5%) received antituberculosis medication to differentiate in-
testinal tuberculosis from CD or because of a first impression of 
intestinal tuberculosis. Thirty patients (2.5%) had a family his-
tory of IBD. With regard to disease location, 733 patients (61.4%) 
had ileocolonic involvement at the time of diagnosis of CD. 
Concomitant UGI disease was detected in 281 patients (23.6%). 
A total of 465 CD patients (39.0%) experienced perianal fis-
tulas. Among them, perianal fistulas were detected before and 
after diagnosis of CD in 318 (68.4%) and 147 patients (31.6%), 
respectively. Among the 147 patients with perianal fistulas 
which were detected after diagnosis of CD, perianal fistulas 
were diagnosed after the occurrence of CD-related surgery and 
complications including nonperianal fistulas, strictures, and 
intra-abdominal abscesses in 15 (10.2%) and 11 patients (7.5%), 
respectively. Perianal fistulas were significantly associated with 
younger age at diagnosis (p<0.001), male gender (p=0.043), di-
agnosis of CD at primary care clinics (p<0.001), and ileocolonic 
involvement (p<0.001) (Table 1). Patients with perianal fistulas 
after diagnosis of CD showed a female predominance (p<0.001) 
and a higher proportion of CD diagnosed at referral hospital 
(p=0.012) compared to those with perianal fistulas before diag-
nosis of CD (Supplementary Table 1).
2. Treatment and clinical outcomes of CD according to the 
presence of perianal fistulas 
During the follow-up period, 748 patients (62.7%) received 
systemic corticosteroids for the treatment of CD. Azathioprine 
and 6-mercaptopurine were administered to 880 patients 
(73.8%), and TNF-α antagonists including infliximab and 
adalimumab were prescribed to 336 patients (28.2%). Rates of 
administration of 5-aminosalicylic acid (5-ASA), antibiotics, 
systemic corticosteroids, azathioprine/6-mercaptopurine, and 
TNF-α antagonist (infliximab) for the treatment of CD were 
significantly higher in patients with perianal fistulas than in 
those without perianal fistulas (Table 2). Moreover, patients 
who experienced perianal fistulas after diagnosis of CD showed 
significantly higher rates of antibiotics, topical corticosteroids, 
methotrexate, and TNF-α antagonist treatment compared to 
those with perianal fistulas before diagnosis of CD (Supplemen-
tary Table 2).
Nonperianal fistulas were found in 192 patients (16.1%) 
during the follow-up period. The median time to complicated 
nonperianal fistulas was 20 months (range, 0 to 202 months) 
from diagnosis of CD. Cumulative rates of nonperianal fistulas 
at 5, 10, and 15 years were 11.1%, 19.5%, and 22.3%, respec-
tively (Fig. 2A). Stricture complications occurred in 338 patients 
(28.3%), and the median time to complicated strictures was 10 
months (range, 0 to 273 months) from diagnosis of CD. Cu-
mulative rates of complicated strictures at 5, 10, and 15 years 
were 21.2%, 32.1%, and 38.4%, respectively (Fig. 2B). Intra-
abdominal abscesses were detected in 163 patients (13.7%), and 
the median time to intra-abdominal abscess formation was 21 
1,382 Patients diagnosed with CD between 1982 and 2008
in a Korean retrospective cohort enrolled from 32 hospitals were included
1,193 CD patients were enrolled
Primary outcome: CD-related complications
Nonperianal fistulas
Strictures
Intra-abdominal abscess
189 Patients were excluded because of
75 A follow-up duration of <12 months or
114 Incomplete medical records
Fig. 1. Flowchart for patient selec-
tion. 
CD, Crohn’s disease. 
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months (range, 0 to 218 months) from diagnosis of CD. Cumu-
lative rates of intra-abdominal abscess at 5, 10, and 15 years 
were 10.0%, 14.7%, and 20.2%, respectively (Fig. 2C). During 
the follow-up, 324 patients (27.2%) with CD underwent surgery 
for refractory disease and/or complications. The median time to 
surgery was 4 months (range, 0 to 193 months) from diagnosis 
of CD. Cumulative rates of surgery at 5, 10, and 15 years were 
21.7%, 30.3%, and 38.5%, respectively (Fig. 2D).
The clinical outcomes of CD according to the presence of 
perianal fistulas are shown in Table 3 and Fig. 3. Complicated 
nonperianal fistulas were significantly more common in pa-
tients with perianal fistulizing CD (18.9%) than in those without 
perianal fistulizing CD (14.3%) (p=0.034). Cumulative rates of 
nonperianal fistulas in patients with versus without perianal 
fistulizing CD were 12.7% versus 10.0%, 21.9% versus 17.8%, 
and 30.0% versus 23.9% at 5, 10, and 20 years, respectively (Fig. 
3A). Furthermore, intra-abdominal abscess was detected more 
frequently in CD patients with perianal fistulas (16.6%) com-
pared to those who had not experienced perianal fistulas (11.8%) 
(p=0.020). Cumulative rates of intra-abdominal abscess in pa-
tients with versus without perianal fistulizing CD were 11.2% 
versus 9.3%, 17.8% versus 12.4%, and 29.3% versus 21.8% at 
5, 10, and 20 years, respectively (Fig. 3B). However, no signifi-
cant difference was found in complicated strictures between 
CD patients with (30.1%) and without perianal fistulas (27.2%) 
(p=0.564). Cumulative rates of complicated strictures in patients 
with versus without perianal fistulizing CD were 22.3% versus 
20.5%, 32.6% versus 31.8%, and 44.2% versus 49.8% at 5, 10, 
and 20 years, respectively (Fig. 3C). There was no significant 
difference in surgical rates between the two groups (p=0.202). 
Table 1. Baseline Characteristics 
Characteristics
Without
perianal fistulas
With
perianal fistulas
p-value
No. of patients 728 (61.0) 465 (39.0) -
Age at diagnosis, yr 29.0±13.3 23.6±8.4 <0.001
Age at diagnosis (Montreal classification)* <0.001
 ≤16 yr (A1)  76 (10.4) 69 (14.8)
 17–40 yr (A2) 521 (71.6) 377 (81.1)
 ≥41 yr (A3) 131 (18.0)  19 (4.1)
Male sex 497 (68.3) 343 (73.8) 0.043
Hospital where patients were diagnosed with CD <0.001
Primary care clinic 111 (15.4) 131 (28.3)
Referral hospital 602 (83.7) 332 (71.7)
Overseas 6 (0.8) 0 
Anti-tuberculosis medication 171 (23.7) 109 (23.6) 0.985
Family history of IBD 16 (2.3) 14 (3.1) 0.382
Location of disease (Montreal classification)* <0.001
Ileum (L1) 203 (27.9) 73 (15.7)
Colon (L2) 107 (14.7) 68 (14.6)
Ileocolon (L3) 409 (56.2) 324 (69.7)
Concomitant UGI disease (L4) 185 (25.4) 96 (20.6) 0.058
Data are presented as number (%) or mean±SD.
CD, Crohn’s disease; IBD, inflammatory bowel disease; UGI, upper gastrointestinal. 
*Age at diagnosis and disease location was determined according to the revised Montreal classification. 
Table 2. Perianal Fistulas and Treatment for Crohn’s Disease
Without
perianal fistulas
(n=728)
With
perianal fistulas
(n=465)
p-value
5-ASA 691 (97.3) 451 (99.1) 0.031
Antibiotics 364 (52.4) 327 (72.7) <0.001
Topical  
corticosteroids
99 (13.8) 63 (13.9) 0.980
Systemic  
corticosteroids
436 (60.3) 312 (68.1) 0.007
Azathioprine/ 
6-mercaptopurine
502 (69.0) 378 (81.3) <0.001
Methotrexate 12 (1.7) 9 (1.9) 0.713
TNF-α antagonist 179 (24.6) 157 (33.8) 0.001
Infliximab 155 (21.3) 145 (31.2) <0.001
Adalimumab 48 (6.6) 28 (6.0) 0.693
Data are presented as number (%).
5-ASA, 5-aminosalicylic acid; TNF-α, tumor necrosis factor-α.
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Cumulative rates of surgery in patients with versus without 
perianal fistulizing CD were 20.7% versus 22.5%, 29.1% versus 
30.9%, and 36.1% versus 40.5% at 5, 10, and 15 years, respec-
tively (Fig. 3D).
In terms of detection time of perianal fistulas, patients with 
perianal fistulas after diagnosis of CD underwent surgery related 
to CD more frequently, compared to those with perianal fistulas 
before diagnosis of CD (p=0.050). However, no significant dif-
ferences in CD-related complications between the two groups 
were found (Supplementary Table 3 and Supplementary Fig. 1).
3. Associated factors of nonperianal fistulas and intra-
abdominal abscesses
Univariable analysis revealed that associated factors of com-
plicated nonperianal fistulas were female gender (p=0.046), ileo-
colonic involvement (p=0.011), concomitant UGI involvement 
(p=0.001), and perianal fistulas (p=0.034). Multivariable analysis 
indicated that independent associated factors of nonperianal 
fistulas were perianal fistulas (adjusted hazard ratio [HR], 1.430; 
95% confidence interval [CI], 1.072 to 1.908; p=0.015), female 
gender (adjusted HR, 1.341; 95% CI, 1.003 to 1.793; p=0.048), 
diagnosis of CD at a referral hospital (adjusted HR, 1.852; 95% 
CI, 1.227 to 2.796; p=0.003), and concomitant UGI involvement 
(adjusted HR, 1.655; 95% CI, 1.222 to 2.241, p=0.001) (Table 4). 
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Fig. 2. Kaplan-Meier curves for clinical outcomes of Crohn’s disease (CD). (A) Cumulative risks of complicated nonperianal fistulas, (B) intra-
abdominal abscess formation, (C) complicated strictures, and (D) CD-related surgery.
Table 3. Perianal Fistulas and Clinical Outcomes of Crohn’s Disease
Without
perianal fistulas
(n=728)
With
perianal fistulas
(n=465)
p-value
CD-related complications
Nonperianal fistulas 104 (14.3) 88 (18.9) 0.034
Strictures 198 (27.2) 140 (30.1) 0.564
Intra-abdominal  
abscess
86 (11.8) 77 (16.6) 0.020
CD-related surgery 202 (27.7) 122 (26.2) 0.202
Data are presented as number (%).
CD, Crohn’s disease.
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Univariable analysis revealed that associated factors of intra-
abdominal abscess formation were 17 to 40 years of age (Mon-
treal classification A2, p=0.020), concomitant UGI involvement 
(p=0.028), and perianal fistulas (p=0.020). Multivariable analysis 
showed that perianal fistulas (adjusted HR, 1.292; 95% CI, 1.005 
to 1.748, p=0.048) and concomitant UGI involvement (adjusted 
HR, 1.510; 95% CI, 1.094 to 2.082; p=0.012) were independently 
associated with the risk of intra-abdominal abscesses. (Table 5).
DISCUSSION 
In this large multicenter cohort study, patients with perianal 
fistulizing CD were more likely to have experienced complica-
tions of nonperianal fistulas and intra-abdominal abscesses, but 
not strictures, than those without perianal fistulizing CD. To the 
best of our knowledge, this study was the first to investigate the 
relationships between perianal fistulizing CD and these disease-
related complications in an Asian population. Our results are 
comparable with those of a population-based cohort study from 
Canada in which CD patients with perianal fistulas were at a 
5-fold increased risk of nonperianal fistulas compared to those 
who had not had perianal fistulas.30 In a multicenter study in 
the United States and Europe, there was also a significant as-
sociation between perianal disease and intestinal fistulas, espe-
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Fig. 3. Kaplan-Meier curves for clinical outcomes of Crohn’s disease (CD) according to the presence of perianal fistula. (A) Cumulative risks of 
complicated nonperianal fistulas, (B) intra-abdominal abscess formation, (C) complicated strictures, and (D) CD-related surgery. 
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cially in CD patients with colonic disease.31 These findings sug-
gest that perianal fistulas are highly associated with nonperianal 
fistulas in CD patients regardless of ethnicity, although perianal 
and nonperianal fistulas might represent distinct phenotypes 
with different behaviors.30 In addition, perianal fistulizing CD 
was associated with the development of intra-abdominal ab-
scess in the disease course, a finding that is consistent with the 
significant relationship between perianal and nonperianal fistu-
las found in this study.
We also found that the presence of perianal fistulas was an 
independent associated factor of the complications including 
nonperianal fistula and intra-abdominal abscess. To date, a few 
cohort studies have reported independent associated factors for 
CD-related complications including nonperianal fistulas, stric-
tures, and intra-abdominal abscesses in Western countries. In a 
single-center cohort study in France, anoperineal disease was a 
significant risk factor for fistulizing complications.32 By contrast, 
a population-based cohort study in the United States33 showed 
that perianal disease at diagnosis of CD was not an indepen-
dent risk factor for developing either stricturing or penetrating 
complications. However, this study did not investigate whether 
perianal disease could predict nonperianal fistulas alone in the 
study population. Considering the relationship between perianal 
and nonperianal fistulas reported by previous studies,30,31 the 
presence of perianal fistulas may be a good clinical indicator 
of complicated nonperianal fistulas and/or intra-abdominal ab-
scesses in CD patients. 
Some previous reports have demonstrated that perianal 
fistulizing CD is a risk factor for poor clinical outcome. In a 
multicenter randomized controlled trial of patients with active 
Table 4. Predictors of Nonperianal Fistula in the Study Population
Variable
Univariate analysis
(log-rank test)
Multivariate analysis
(Cox proportional hazard models)
% p-value Adjusted HR 95% CI p-value
Age at diagnosis (Montreal classification)* 0.271 - - -
 ≤16 yr (A1) 17.2
 17-40 yr (A2) 16.8
 ≥41 yr (A3) 10.7
Sex 0.046
Male 14.4 1 (reference)
Female 20.1 1.341 1.003–1.793 0.048
Hospital where patients were diagnosed with CD 0.068
Primary care clinic 11.2 1 (reference)
Referral hospital 17.3 1.852 1.227–2.796 0.003
Overseas 16.7 4.393  0.214–19.027 0.489
Anti-tuberculosis medication 0.927 - - -
No 15.7
Yes 17.1
Family history of IBD 0.169 - - -
No 16.4
Yes 6.7
Location of disease (Montreal classification)* 0.011
Ileum (L1) 14.1 1 (reference)
Colon (L2) 8.6 0.627 0.353–1.113 0.111
Ileocolon (L3) 18.7 1.263 0.887–1.798 0.195
Concomitant UGI disease (L4) 0.001
No 14.0 1 (reference)
Yes 22.7 1.655 1.222–2.241 0.001
Perianal fistula 0.034
No 14.3 1 (reference)
Yes 18.9 1.430 1.072–1.908 0.015
HR, hazard ratio; CI, confidence interval; CD, Crohn’s disease; IBD, inflammatory bowel disease; UGI, upper gastrointestinal. 
*Age at diagnosis and disease location was determined according to the revised Montreal classification. 
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CD, perianal disease increased the risk of resistance to corti-
costeroids.34 Beaugerie et al.35 showed that perianal disease at 
initial presentation of CD was associated with disabling clinical 
course related to corticosteroid dependence, hospitalization, and 
surgical intestinal resection for disease flares. In a retrospec-
tive study, patients with perianal fistulizing CD had a 1.7-fold 
increased risk of surgery compared to those who had not had 
perianal fistulizing CD.36 Moreover, a recent study reported that 
patients with perianal CD had a higher risk of reoperation after 
primary bowel resection related to CD compared to those with-
out perianal CD.37 However, in this observational cohort study, 
presentation of perianal fistulas in CD was not associated with 
the risk of CD-related surgery. CD patients who required surgery 
for free perforation experienced less intra-abdominal abscess, 
perianal and intestinal fistulas, but were significantly associated 
with bowel strictures in a retrospective study of results from the 
CONNECT.24 Taken together, it remains unclear whether perianal 
fistulas are the indicator of bowel resection in patients with CD. 
However, patients with perianal fistulizing CD also required 
more frequent corticosteroids, immunomodulators, and TNF-α 
antagonists for the treatment of CD than those without perianal 
fistulizing CD, suggesting that perianal fistulizing CD is likely 
to be a severe relapsing disease during follow-up. Therefore, 
patients with perianal fistulizing CD should be carefully moni-
tored for the development of disabling complications including 
nonperianal fistulas and intra-abdominal abscesses. In addition, 
early treatment with TNF-α antagonists can be considered to 
prevent complications and reduce surgical requirements in pa-
tients with perianal fistulizing CD, as well as those in Western 
countries.38 
Table 5. Predictors of Intra-abdominal Abscess in the Study Population
Variable
Univariate analysis
(log-rank test)
Multivariate analysis
(Cox proportional hazard models)
% p-value Adjusted HR 95% CI p-value
Age at diagnosis (Montreal classification)* 0.020
≤16 yr (A1) 9.0 1 (reference)
17-40 yr (A2) 15.4 1.816 0.989–3.643 0.076
≥41 yr (A3) 8.0 1.153 0.544–2.444 0.710
Sex 0.338 - - -
Male 14.0
Female 12.7
Hospital where patients were diagnosed with CD 0.236 - - -
Primary care clinic 10.7
Referral hospital 14.0
Overseas 33.3
Anti-tuberculosis medication 0.807 - - -
No 13.4
Yes 14.3
Family history of IBD 0.097 - - --
No 13.9
Yes 3.3
Location of disease (Montreal classification)* 0.099 - - -
Ileum (L1) 12.7
Colon (L2) 8.6
Ileocolon (L3) 15.1
Concomitant UGI disease (L4) 0.028
No 12.4 1 (reference)
Yes 17.8 1.510 1.094–2.082 0.012
Perianal Fistula 0.020
No 11.8 1 (reference)
Yes 16.6 1.292 1.005–1.748 0.048
HR, hazard ratio; CI, confidence interval; CD, Crohn’s disease; IBD, inflammatory bowel disease; UGI, upper gastrointestinal. 
*Age at diagnosis and disease location was determined according to the revised Montreal classification. 
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In terms of detection time of perianal fistulas, patients with 
perianal fistulas after CD diagnosis required intestinal resection 
for medical refractoriness and/or complications of CD except 
perianal lesions more frequently, compared to presentation of 
perianal fistulas before diagnosis of CD regardless of CD-related 
complications. In this study, the patients who experienced 
perianal fistulas following diagnosis of CD also required more 
intensive medical treatment including antibiotics, methotrex-
ate and TNF-α antagonist for treatment of active CD than those 
with perianal fistulas before diagnosis of CD. It remains unclear 
how the detection time of perianal fistulas affects the clinical 
course of disease in CD, but the presentation of perianal fistulas 
after diagnosis of CD might be an indicator of disease activity 
and aggressive clinical course.
The cumulative frequency of perianal fistulizing CD at refer-
ral centers has been reported to range from 13% to 38% in 
Western countries.39 In the present multicenter cohort study, 
the prevalence of perianal fistulas in Korean patients with CD 
was 39% at referral hospitals. A previous hospital-based study 
at a tertiary care center in Korea showed that the prevalence of 
perianal fistulas was 46.8%.40 Thus, perianal fistulas may occur 
more frequently in Korean patients with CD than in patients 
with CD from Western countries. However, the high prevalence 
of perianal fistulas found by previous studies in Korea might 
have been due to referrals to tertiary care centers, because the 
presence of perianal fistulas requires a multidisciplinary ap-
proach for management of CD. This level of care is available 
at tertiary care centers rather than primary care clinics. Further 
population-based studies are needed to determine whether 
Korean patients with CD show a higher prevalence of perianal 
fistulas compared to Caucasians.
In this study, perianal fistulas were significantly more com-
mon in CD patients of younger age, male gender, and ileoco-
lonic involvement and in those who were diagnosed at primary 
care clinics. Patients who are younger when first diagnosed 
with CD appear to be at the greatest risk of perianal fistulas.19 In 
previous reports, age <40 years at diagnosis was a risk factor for 
fistulizing disease including perianal fistulas.30,32 
Some previous studies have reported that male patients with 
CD are more likely to have perianal fistulas compared to female 
patients with CD,41,42 however, there was no significant gender 
difference with respect to the presence of perianal fistulas in 
a population-based study.43 Male gender might be a possible 
risk factor for perianal fistulizing CD in spite of the conflicting 
results reported thus far. With respect to the location of disease, 
earlier studies in Western countries have reported that patients 
with isolated ileal CD are at the lowest risk of perianal fistulas.19 
The negative association between perianal fistulas and isolated 
ileal disease was also found in the present study. However, peri-
anal fistulas occurred most often in patients with ileocolonic 
disease in our cohort, in contrast to previous studies in Western 
countries, which reported that CD patients with active rectal dis-
ease are most likely to develop perianal fistulas.19 In accordance 
with the results of previous studies,40,44 the Korean population in 
this study was more likely to have ileocolonic CD compared to 
Caucasians, especially in those with perianal fistulas. Interest-
ingly, both male predominance and more ileocolonic involve-
ment is the epidemiologic characteristics of Korean CD patients 
compared to Western countries.45 It may be associated with the 
high prevalence of perianal fistulas in Korean. 
The frequency of perianal fistulas was relatively high in 
patients who were diagnosed with CD at primary care clinics 
compared to those diagnosed at referral hospitals. The reasons 
for this observation remain unclear, but possible explanations 
include both the large proportion (68%) of perianal fistulas 
that were detected before diagnosis of CD and the high degree 
of suspicion of CD among primary care physicians managing 
young patients who present with perianal fistulas in Korea. 
Some of the patients who present with perianal fistulas might 
prefer primary care clinics specialized for coloproctology in 
which surgeons work, although the information on the specialty 
of primary care clinics was not available in this study.
We also observed that concomitant UGI involvement was an 
independent associated factor for both complicated nonperi-
anal fistulas and/or intra-abdominal abscesses in patients with 
CD. In accordance with our results, Tang et al.30 reported that 
fistulizing CD including perianal fistulas was associated with a 
predisposition to UGI disease in Canadian patients. Moreover, 
UGI involvement was significantly associated with the time to 
first major abdominal surgery in a population-based cohort 
study from the United States.46 These findings suggest that UGI 
involvement is also a marker for poor clinical outcomes, espe-
cially penetrating complications, in patients with CD regardless 
of ethnicity. 
This multicenter cohort study has several limitations. First, 
further information regarding the characteristics of perianal fis-
tulas including type, activity, treatment, and outcomes of lesion 
was not available because of its retrospective nature. Second, a 
variety of confounding factors including smoking, clinical dis-
ease activity, and biological markers such as C-reactive protein47 
could not be controlled for due to a lack of medical records. 
Finally, this was a hospital-based cohort study that included pa-
tients from 32 referral hospitals. Thus, it may be biased toward 
more severe disease compared to population-based studies and 
may overestimate disease-related complications in a Korean 
population.
In conclusion, the presence of perianal fistulas was associated 
with the development of nonperianal fistulas and intra-abdom-
inal abscesses in Korean patients with CD. Therefore, patients 
with perianal fistulizing CD should be carefully monitored for 
complicated nonperianal fistulas and intra-abdominal abscesses.
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